FDA rejects Valeant's nail fungus treatment; Eleven Bio nabs collaboration pact with ThromboGenics; EC approves Stribild;

@FierceBiotech: Trending this weekend: Top 10 Biotech CEO Pay Packages of 2012. Feature | Follow @FierceBiotech

@JohnCFierce: From earlier today: AstraZeneca scoops up PhIII cardio drug in $443M Omthera buyout (did AZ pay too much?) Story | Follow @JohnCFierce

> The FDA has rejected Valeant Pharmaceutical's ($VRX) nail fungus therapy efinaconazole, citing questions on the container closure apparatus it uses. Valeant says the questions can all be handled in a timely fashion and expects to get back to the FDA as soon as possible. Story

> Cambridge, MA-based Eleven Biotherapeutics has struck a deal to collaborate with ThromboGenics NV on a protein therapeutic for ophthalmic disease. The collaboration aims to employ Eleven's proprietary AMP-Rx protein design technology to optimize a therapeutic of ThromboGenics' selection.  The biologic will be designed to treat back-of-the-eye diseases such as diabetic macular edema. None of the terms were released. Release

> The European Commission has approved Gilead's ($GILD) HIV drug Stribild. Story

> Shares of ReNeuron jumped on interim data for its stem cell therapy for stroke damage. Report

> Helsinn has decided to advance the development of elsiglutide into Phase IIb for the prevention of chemotherapy-induced diarrhea. Release

Medical Device News

@FierceMedDev: Roche launches DNA kit amid applied science shake-up. Article | Follow @FierceMedDev

 @DamianFierce: In case you missed it Monday, Valeant is buying Bausch + Lomb for $8.7B. Report | Follow @DamianFierce

> Medical device firms still passing tax on to hospitals, group says. Item

> Sluggish FDA device approvals frustrate cardiologists. Report

> Paris, je stent: Fierce's 2013 EuroPCR coverage. More

> FDA sticks 'deadly' tag on Cook's stent recall. News

Pharma News

@FiercePharma: India's Sun Pharma beats on profits, with 31% revenue hike to about $550M. More | Follow @FiercePharma

@EricPFierce: U.S. arrests 2 Pakistani men for selling controlled substances via the Internet. Interpol tracks them to London. Report | Follow @EricPFierce

> Feds subpoena Forest Labs in Tudorza Pressair investigation. Story

> Drugmakers to reap $115B in sales as Obamacare rolls on, study finds. Report

> ISTA excluded from Medicare in $33.5M off-label settlement. Article

Pharma Manufacturing News

> India takes another step to meet looming EU API rules. Story

> FDA tracking down new outbreak tied to compounded drug. More

> U.S. holds two Pakistani men for Internet sales of controlled substances. Report

> Indian regulators unsure how to react to USFDA actions. Article

CRO News

> Parexel expands eClinical presence in China. Article

> India amps up clinical trial consent regulations. Report

> Corgenix inks cancer deal with Lilly. More

> Nordion sells off drug unit for $200M, focuses on contracting. Story

Biotech IT News

> Boehringer VP impressed by wireless pill bottle. Item

> Treato sees success for Biogen in social media buzz. Article

> Genentech asks iPad gamers to save San Fran from mutant cheese. More

> Chinese trial data hackers reportedly active again. Report

Biotech Research News

 @EmilyMFierce: Universal flu vaccine effective in preclinical studies. More | Follow @EmilyMFierce

> Stem cell cloning study contained errors. Story

> Stabilizing a gene reverses schizophrenia in mice. Report

> New study refutes Targretin claim for treatment of Alzheimer's. Article

And Finally… In a new report in The Lancet, investigators confirm that several of the new bird flu cases seen in China recently have proven to be resistant to Tamiflu. Story